NASDAQ:IOVA - Iovance Biotherapeutics Stock Price, Price Target & More

$14.85 0.00 (0.00 %)
(As of 04/27/2018 04:26 AM ET)
Previous Close$14.85
Today's Range$14.70 - $15.00
52-Week Range$4.45 - $19.90
Volume509,541 shs
Average Volume1.04 million shs
Market Capitalization$1.28 billion
P/E Ratio-10.53
Dividend YieldN/A
Beta5.75

About Iovance Biotherapeutics (NASDAQ:IOVA)

Iovance Biotherapeutics logoIovance Biotherapeutics, Inc., formerly Lion Biotechnologies, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient's own immune system to eradicate cancer cells. The Company's lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients' tumors, for the treatment of metastatic melanoma. As of December 31, 2016, it had an on-going Phase II clinical trial of its lead product candidate, LN-144, TIL for the treatment of metastatic melanoma. The Company is developing LN-145 to treat cervical and head and neck cancers. It is collaborating with the National Cancer Institute to evaluate unmodified TIL in other solid tumor indications, such as ocular melanoma, bladder, breast and lung cancer. It is collaborating with the NCI to evaluate TIL in combination with the checkpoint inhibitor, Keytruda.

Receive IOVA News and Ratings via Email

Sign-up to receive the latest news and ratings for IOVA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:IOVA
CUSIPN/A
Phone650-260-7120

Debt

Debt-to-Equity RatioN/A
Current Ratio15.10%
Quick Ratio15.10%

Price-To-Earnings

Trailing P/E Ratio-10.53
Forward P/E Ratio-11.88
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.71 per share
Price / Book8.68

Profitability

EPS (Most Recent Fiscal Year)($1.41)
Net Income$-92,060,000.00
Net MarginsN/A
Return on Equity-62.42%
Return on Assets-59.14%

Miscellaneous

Employees63
Outstanding Shares89,450,000

Iovance Biotherapeutics (NASDAQ:IOVA) Frequently Asked Questions

What is Iovance Biotherapeutics' stock symbol?

Iovance Biotherapeutics trades on the NASDAQ under the ticker symbol "IOVA."

How were Iovance Biotherapeutics' earnings last quarter?

Iovance Biotherapeutics Inc (NASDAQ:IOVA) announced its quarterly earnings data on Monday, March, 12th. The biotechnology company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.32) by $0.04. View Iovance Biotherapeutics' Earnings History.

What price target have analysts set for IOVA?

9 brokers have issued 12-month price targets for Iovance Biotherapeutics' shares. Their forecasts range from $13.00 to $31.00. On average, they expect Iovance Biotherapeutics' stock price to reach $20.9375 in the next year. View Analyst Ratings for Iovance Biotherapeutics.

What are Wall Street analysts saying about Iovance Biotherapeutics stock?

Here are some recent quotes from research analysts about Iovance Biotherapeutics stock:
  • 1. According to Zacks Investment Research, "Iovance Biotherapeutics, Inc. is a biopharmaceutical company. It focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient's own immune system to eradicate cancer cells. Iovance Biotherapeutics Inc., formerly known as Lion Biotechnologies Inc., is based in SAN CARLOS, United States. " (1/20/2018)
  • 2. Cowen Inc analysts commented, "IOVA reported that the first patient in LN-145’s Phase II cervical cancer study has been." (8/16/2017)
  • 3. HC Wainwright analysts commented, "We project that one or more of these patients who achieved early PRs could transform to CRs with more follow up time as the infused TILs continue to act." (6/7/2017)

Who are some of Iovance Biotherapeutics' key competitors?

Who are Iovance Biotherapeutics' key executives?

Iovance Biotherapeutics' management team includes the folowing people:
  • Wayne Rothbaum, Interim Chairman of the Board
  • Maria Fardis Ph.D., President, Chief Executive Officer
  • Gregory T. Schiffman, Chief Financial Officer
  • James G. Bender Ph.D., Vice President
  • Iain D Dukes, Director
  • , Bio & Compensation - 
  • Ryan D. Maynard, Director
  • Sanford J. Hillsberg J.D., Independent Director
  • Merrill A. McPeak USAF, Independent Director
  • Jay Venkatesan M.D., Independent Director

Has Iovance Biotherapeutics been receiving favorable news coverage?

News articles about IOVA stock have been trending somewhat positive this week, Accern Sentiment reports. The research group identifies negative and positive news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Iovance Biotherapeutics earned a coverage optimism score of 0.15 on Accern's scale. They also assigned media stories about the biotechnology company an impact score of 45.91 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near term.

How do I buy shares of Iovance Biotherapeutics?

Shares of IOVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Iovance Biotherapeutics' stock price today?

One share of IOVA stock can currently be purchased for approximately $14.85.

How big of a company is Iovance Biotherapeutics?

Iovance Biotherapeutics has a market capitalization of $1.28 billion. The biotechnology company earns $-92,060,000.00 in net income (profit) each year or ($1.41) on an earnings per share basis. Iovance Biotherapeutics employs 63 workers across the globe.

How can I contact Iovance Biotherapeutics?

Iovance Biotherapeutics' mailing address is 999 SKYWAY ROAD SUITE 150, SAN CARLOS CA, 94070. The biotechnology company can be reached via phone at 650-260-7120 or via email at [email protected]


MarketBeat Community Rating for Iovance Biotherapeutics (IOVA)

Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  270 (Vote Outperform)
Underperform Votes:  120 (Vote Underperform)
Total Votes:  390
MarketBeat's community ratings are surveys of what our community members think about Iovance Biotherapeutics and other stocks. Vote "Outperform" if you believe IOVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IOVA will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Iovance Biotherapeutics (NASDAQ:IOVA) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
9 Wall Street analysts have issued ratings and price targets for Iovance Biotherapeutics in the last 12 months. Their average twelve-month price target is $20.9375, suggesting that the stock has a possible upside of 40.99%. The high price target for IOVA is $31.00 and the low price target for IOVA is $13.00. There are currently 9 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.002.893.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $20.9375$20.9375$16.0625$14.9286
Price Target Upside: 40.99% upside9.33% upside39.67% upside104.50% upside

Iovance Biotherapeutics (NASDAQ:IOVA) Consensus Price Target History

Price Target History for Iovance Biotherapeutics (NASDAQ:IOVA)

Iovance Biotherapeutics (NASDAQ:IOVA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/10/2018B. RileyUpgradeNeutral -> Buy$22.00LowView Rating Details
3/13/2018HC WainwrightSet Price TargetBuy$22.00HighView Rating Details
2/9/2018Jefferies GroupBoost Price TargetBuy$31.00LowView Rating Details
1/31/2018OppenheimerBoost Price TargetOutperform -> Outperform$13.00 -> $19.00LowView Rating Details
1/29/2018Wells FargoReiterated RatingBuy$23.00MediumView Rating Details
1/22/2018Chardan CapitalReiterated RatingBuyHighView Rating Details
10/25/2017FBR & CoReiterated RatingBuy$17.50N/AView Rating Details
8/16/2017CowenReiterated RatingBuyMediumView Rating Details
5/10/2017Rodman & RenshawInitiated CoverageBuy -> Buy$13.00LowView Rating Details
3/8/2017Roth CapitalSet Price TargetBuy$14.00LowView Rating Details
6/6/2016SunTrust BanksDowngradeBuy -> Neutral$37.00 -> $30.50N/AView Rating Details
(Data available from 4/27/2016 forward)

Earnings

Iovance Biotherapeutics (NASDAQ:IOVA) Earnings History and Estimates Chart

Earnings by Quarter for Iovance Biotherapeutics (NASDAQ:IOVA)

Iovance Biotherapeutics (NASDAQ:IOVA) Earnings Estimates

2018 EPS Consensus Estimate: ($1.32)
2019 EPS Consensus Estimate: ($1.51)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20184($0.34)($0.30)($0.33)
Q2 20184($0.34)($0.30)($0.33)
Q3 20184($0.34)($0.31)($0.33)
Q4 20184($0.35)($0.31)($0.34)
Q1 20191($0.37)($0.37)($0.37)
Q2 20191($0.38)($0.38)($0.38)
Q3 20191($0.39)($0.39)($0.39)
Q4 20191($0.37)($0.37)($0.37)

Iovance Biotherapeutics (NASDAQ IOVA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/12/2018Q4 2017($0.3220)($0.36)ViewListenView Earnings Details
10/31/2017Q3 2017($0.34)($0.35)ViewN/AView Earnings Details
8/1/2017Q2 2017($0.35)($0.37)ViewN/AView Earnings Details
5/1/2017Q1 2017($0.28)($0.33)ViewListenView Earnings Details
3/7/2017Q4 2016($0.25)($0.25)ViewListenView Earnings Details
11/4/2016Q316($0.22)($0.32)ViewN/AView Earnings Details
8/8/2016Q2 2016($0.19)($0.23)ViewN/AView Earnings Details
5/9/2016Q1 2016($0.16)($0.14)ViewN/AView Earnings Details
3/10/2016Q4($0.20)($0.20)ViewN/AView Earnings Details
11/5/2015Q3 2015($0.20)($0.16)ViewN/AView Earnings Details
8/10/2015Q2 2015($0.17)($0.14)ViewN/AView Earnings Details
5/11/2015Q1 2015($0.11)($0.14)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Iovance Biotherapeutics (NASDAQ:IOVA) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Iovance Biotherapeutics (NASDAQ IOVA) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 13.20%
Institutional Ownership Percentage: 64.46%
Insider Trading History for Iovance Biotherapeutics (NASDAQ:IOVA)
Institutional Ownership by Quarter for Iovance Biotherapeutics (NASDAQ:IOVA)

Iovance Biotherapeutics (NASDAQ IOVA) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/25/2016Sanford HillsbergDirectorSell54,000$8.95$483,300.00View SEC Filing  
8/22/2016Sanford HillsbergDirectorSell54,000$9.11$491,940.00View SEC Filing  
9/8/2015Sanford HillsbergDirectorSell32,500$6.99$227,175.00View SEC Filing  
5/6/2015Sanford HillsbergDirectorSell50,000$10.00$500,000.00View SEC Filing  
11/5/2013Manish SinghCEOBuy125,000$2.00$250,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Iovance Biotherapeutics (NASDAQ IOVA) News Headlines

Source:
DateHeadline
Financial Contrast: Iovance Biotherapeutics (IOVA) & Its CompetitorsFinancial Contrast: Iovance Biotherapeutics (IOVA) & Its Competitors
www.americanbankingnews.com - April 27 at 3:32 AM
-$0.29 Earnings Per Share Expected for Iovance Biotherapeutics Inc (IOVA) This Quarter-$0.29 Earnings Per Share Expected for Iovance Biotherapeutics Inc (IOVA) This Quarter
www.americanbankingnews.com - April 23 at 11:20 AM
Iovance Biotherapeutics Inc (IOVA) Receives Consensus Rating of "Buy" from AnalystsIovance Biotherapeutics Inc (IOVA) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - April 12 at 5:35 AM
Iovance Biotherapeutics (IOVA) Lifted to "Buy" at B. RileyIovance Biotherapeutics (IOVA) Lifted to "Buy" at B. Riley
www.americanbankingnews.com - April 10 at 8:37 AM
Jefferies Group Reiterates Buy Rating for Iovance Biotherapeutics (IOVA)Jefferies Group Reiterates Buy Rating for Iovance Biotherapeutics (IOVA)
www.americanbankingnews.com - April 9 at 1:27 PM
Iovance Biotherapeutics (IOVA) Upgraded at Zacks Investment ResearchIovance Biotherapeutics (IOVA) Upgraded at Zacks Investment Research
www.americanbankingnews.com - April 7 at 11:38 AM
Iovance Biotherapeutics Inc (IOVA) Expected to Post Earnings of -$0.29 Per ShareIovance Biotherapeutics Inc (IOVA) Expected to Post Earnings of -$0.29 Per Share
www.americanbankingnews.com - April 6 at 11:29 AM
Iovance Biotherapeutics (IOVA) "Buy" Rating Reiterated at FBR & CoIovance Biotherapeutics' (IOVA) "Buy" Rating Reiterated at FBR & Co
www.americanbankingnews.com - April 5 at 2:25 PM
Iovance Biotherapeutics (IOVA) Downgraded by BidaskClub to "Buy"Iovance Biotherapeutics (IOVA) Downgraded by BidaskClub to "Buy"
www.americanbankingnews.com - April 5 at 12:30 AM
Iovance Biotherapeutics (IOVA) Given a $16.00 Price Target at HC WainwrightIovance Biotherapeutics (IOVA) Given a $16.00 Price Target at HC Wainwright
www.americanbankingnews.com - April 4 at 2:26 PM
Iovance Biotherapeutics (IOVA) Lifted to "Buy" at ValuEngineIovance Biotherapeutics (IOVA) Lifted to "Buy" at ValuEngine
www.americanbankingnews.com - April 3 at 1:22 PM
Iovance Biotherapeutics (IOVA) PT Set at $13.00 by OppenheimerIovance Biotherapeutics (IOVA) PT Set at $13.00 by Oppenheimer
www.americanbankingnews.com - April 2 at 3:42 PM
Iovance Biotherapeutics (IOVA) PT Raised to $18.00Iovance Biotherapeutics (IOVA) PT Raised to $18.00
www.americanbankingnews.com - April 2 at 3:15 PM
Contrasting Iovance Biotherapeutics (IOVA) and The CompetitionContrasting Iovance Biotherapeutics (IOVA) and The Competition
www.americanbankingnews.com - April 1 at 7:22 AM
Iovance Biotherapeutics (IOVA) Rating Increased to Buy at Zacks Investment ResearchIovance Biotherapeutics (IOVA) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - March 30 at 11:42 PM
Zacks Investment Research Downgrades Iovance Biotherapeutics (IOVA) to HoldZacks Investment Research Downgrades Iovance Biotherapeutics (IOVA) to Hold
www.americanbankingnews.com - March 30 at 8:24 PM
Iovance Biotherapeutics (IOVA) Stock Rating Upgraded by BidaskClubIovance Biotherapeutics (IOVA) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - March 27 at 4:34 PM
Iovance Biotherapeutics (IOVA) Upgraded by ValuEngine to HoldIovance Biotherapeutics (IOVA) Upgraded by ValuEngine to Hold
www.americanbankingnews.com - March 25 at 4:48 PM
Iovance Biotherapeutics (IOVA) Given a $22.00 Price Target by HC Wainwright AnalystsIovance Biotherapeutics (IOVA) Given a $22.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - March 18 at 10:24 AM
Iovance Biotherapeutics Inc (IOVA) Receives Average Rating of "Buy" from AnalystsIovance Biotherapeutics Inc (IOVA) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - March 18 at 7:28 AM
Iovance Biotherapeutics (IOVA) Lowered to "Buy" at BidaskClubIovance Biotherapeutics (IOVA) Lowered to "Buy" at BidaskClub
www.americanbankingnews.com - March 16 at 11:34 PM
B. Riley Brokers Boost Earnings Estimates for Iovance Biotherapeutics Inc (IOVA)B. Riley Brokers Boost Earnings Estimates for Iovance Biotherapeutics Inc (IOVA)
www.americanbankingnews.com - March 15 at 9:22 AM
Iovance Biotherapeutics Inc Forecasted to Earn Q3 2018 Earnings of ($0.31) Per Share (IOVA)Iovance Biotherapeutics Inc Forecasted to Earn Q3 2018 Earnings of ($0.31) Per Share (IOVA)
www.americanbankingnews.com - March 15 at 8:15 AM
Oppenheimer Comments on Iovance Biotherapeutics Incs Q1 2018 Earnings (IOVA)Oppenheimer Comments on Iovance Biotherapeutics Inc's Q1 2018 Earnings (IOVA)
www.americanbankingnews.com - March 15 at 7:57 AM
Analysts Offer Predictions for Iovance Biotherapeutics Incs Q1 2018 Earnings (IOVA)Analysts Offer Predictions for Iovance Biotherapeutics Inc's Q1 2018 Earnings (IOVA)
www.americanbankingnews.com - March 14 at 7:20 AM
Iovance Biotherapeutics (IOVA) Price Target Raised to $22.00Iovance Biotherapeutics (IOVA) Price Target Raised to $22.00
www.americanbankingnews.com - March 13 at 1:38 PM
Iovance Biotherapeutics (IOVA) Announces Quarterly  Earnings Results, Misses Estimates By $0.04 EPSIovance Biotherapeutics (IOVA) Announces Quarterly Earnings Results, Misses Estimates By $0.04 EPS
www.americanbankingnews.com - March 13 at 10:39 AM
Iovance Biotherapeutics posts 4Q lossIovance Biotherapeutics posts 4Q loss
finance.yahoo.com - March 12 at 4:44 PM
Iovance Biotherapeutics Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Corporate UpdateIovance Biotherapeutics Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - March 12 at 4:44 PM
Iovance Biotherapeutics to Host Conference Call to Discuss Fourth Quarter and Year-End 2017 Financial Results and ... - GlobeNewswire (press release)Iovance Biotherapeutics to Host Conference Call to Discuss Fourth Quarter and Year-End 2017 Financial Results and ... - GlobeNewswire (press release)
globenewswire.com - March 10 at 4:49 PM
Iovance Biotherapeutics to Host Conference Call to Discuss Fourth Quarter and Year-End 2017 Financial Results and Provide a Corporate Update on Monday, March 12, 2018Iovance Biotherapeutics to Host Conference Call to Discuss Fourth Quarter and Year-End 2017 Financial Results and Provide a Corporate Update on Monday, March 12, 2018
finance.yahoo.com - March 8 at 10:30 AM
Iovance Biotherapeutics to Present at Two Upcoming Investor Conferences in MarchIovance Biotherapeutics to Present at Two Upcoming Investor Conferences in March
finance.yahoo.com - March 7 at 9:48 AM
Prosight Management LP Acquires New Stake in Iovance Biotherapeutics Inc (IOVA)Prosight Management LP Acquires New Stake in Iovance Biotherapeutics Inc (IOVA)
www.americanbankingnews.com - March 5 at 4:07 PM
Is a Surprise Coming for Lion Biotechnologies (IOVA) This Earnings Season?Is a Surprise Coming for Lion Biotechnologies (IOVA) This Earnings Season?
finance.yahoo.com - March 5 at 10:21 AM
Iovance Biotherapeutics Inc (IOVA) Shares Sold by Broadfin Capital LLCIovance Biotherapeutics Inc (IOVA) Shares Sold by Broadfin Capital LLC
www.americanbankingnews.com - March 2 at 5:08 AM
Iovance Biotherapeutics Appoints Michael Weiser, M.D., Ph.D., to its Board of DirectorsIovance Biotherapeutics Appoints Michael Weiser, M.D., Ph.D., to its Board of Directors
finance.yahoo.com - March 1 at 9:24 AM
Iovance Biotherapeutics Target of Unusually Large Options Trading (IOVA)Iovance Biotherapeutics Target of Unusually Large Options Trading (IOVA)
www.americanbankingnews.com - February 27 at 8:38 AM
Iovance Biotherapeutics (IOVA) Rating Reiterated by B. RileyIovance Biotherapeutics (IOVA) Rating Reiterated by B. Riley
www.americanbankingnews.com - February 24 at 3:50 PM
Iovance Biotherapeutics Inc (IOVA) Receives Average Rating of "Buy" from BrokeragesIovance Biotherapeutics Inc (IOVA) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - February 21 at 5:04 AM
Biotech Heats Up as Fear of Missing Out ReturnsBiotech Heats Up as Fear of Missing Out Returns
finance.yahoo.com - February 14 at 3:27 PM
Iovance Biotherapeutics to Present at the RBC Capital Markets 2018 Global Healthcare ConferenceIovance Biotherapeutics to Present at the RBC Capital Markets 2018 Global Healthcare Conference
finance.yahoo.com - February 14 at 3:27 PM
 Brokerages Anticipate Iovance Biotherapeutics Inc (IOVA) to Announce -$0.32 EPS Brokerages Anticipate Iovance Biotherapeutics Inc (IOVA) to Announce -$0.32 EPS
www.americanbankingnews.com - February 14 at 3:10 PM
Iovance Biotherapeutics (IOVA) Given New $31.00 Price Target at Jefferies GroupIovance Biotherapeutics (IOVA) Given New $31.00 Price Target at Jefferies Group
www.americanbankingnews.com - February 9 at 10:36 PM
Iovance Biotherapeutics Inc (NASDAQ:IOVA) And The Healthcare Sector Outlook 2018Iovance Biotherapeutics Inc (NASDAQ:IOVA) And The Healthcare Sector Outlook 2018
finance.yahoo.com - February 4 at 3:28 PM
Iovance Biotherapeutics (IOVA) Upgraded at BidaskClubIovance Biotherapeutics (IOVA) Upgraded at BidaskClub
www.americanbankingnews.com - February 3 at 7:40 PM
Iovance Biotherapeutics Inc to Post FY2017 Earnings of ($1.38) Per Share, Oppenheimer Forecasts (IOVA)Iovance Biotherapeutics Inc to Post FY2017 Earnings of ($1.38) Per Share, Oppenheimer Forecasts (IOVA)
www.americanbankingnews.com - February 2 at 10:24 AM
Iovance Biotherapeutics (IOVA) in Focus: Stock Moves 5.1% Higher - NasdaqIovance Biotherapeutics (IOVA) in Focus: Stock Moves 5.1% Higher - Nasdaq
www.nasdaq.com - January 31 at 3:24 PM
Biotech Forum Daily Digest For January 31st - Iovance ... - Seeking AlphaBiotech Forum Daily Digest For January 31st - Iovance ... - Seeking Alpha
seekingalpha.com - January 31 at 3:24 PM
Iovance Biotherapeutics (IOVA) Price Target Raised to $19.00Iovance Biotherapeutics (IOVA) Price Target Raised to $19.00
www.americanbankingnews.com - January 31 at 2:50 PM
Iovance Biotherapeutics (IOVA) in Focus: Stock Moves 5.1% HigherIovance Biotherapeutics (IOVA) in Focus: Stock Moves 5.1% Higher
finance.yahoo.com - January 30 at 3:24 PM

SEC Filings

Iovance Biotherapeutics (NASDAQ:IOVA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Iovance Biotherapeutics (NASDAQ:IOVA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Iovance Biotherapeutics (NASDAQ IOVA) Stock Chart for Friday, April, 27, 2018

Loading chart…

This page was last updated on 4/27/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.